Future prospects for vaccination of dogs and cats

This is the latest version of this item.

Abstract

[Extract] Veterinarians in clinical practice are quite familiar with the characteristics of inactivated and modified live vaccines intended to help protect dogs and cats against bacterial and viral infectious diseases. Indeed, generations of veterinary students have been required to learn the relative advantages and disadvantages of inactivated (i.e., killed) and modified-live (i.e., attenuated) vaccines. Most of the vaccines currently available for use in dogs and cats can be placed into one or other of these two 'conventional' categories, although it is perhaps a little unfair to lump them together and describe them as conventional, since some are relatively sophisticated (e.g., a modified-live, temperature-sensitive mutant virus). Relatively few currently-available canine and feline vaccines are based on recombinant DNA technology. However, it seems likely that – over the next few years – a startling profusion of novel vaccines will be marketed for use in cats and dogs. Most of these will be based on recombinant DNA technology and not all of them will be prophylactic; some will most likely be therapeutic.

Available Versions of this Item

• Future prospects for vaccination of dogs and cats. (deposited 13 Oct 2011 17:30)
  • Future prospects for vaccination of cats and dogs. (deposited 13 Oct 2011 17:33)
    • Future prospects for vaccination of dogs and cats. (deposited 13 Oct 2011 17:34) [Currently Displayed]